Mar 30, 2009 - Seattle Genetics, Inc. today announced that the U.S. FDA has granted fast track designation to SGN-35 for the treatment of Hodgkin lymphoma. SGN-35, an antibody-drug conjugate (ADC), is in an ongoing pivotal trial under a Special Protocol Assessment (SPA) from the FDA for relapsed or refractory Hodgkin lymphoma.
The details can be read here.
No comments:
Post a Comment